STAT+: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon
STAT News · LC
A Roivant lung disease drug has succeeded in a mid-stage study. But the drug’s origins are another fascinating aspect to the story.
Read the original at STAT News →
Open in TruthVane →